Stoke Therapeutics names Thomas McCauley chief scientific officer

Stoke Therapeutics appointed Thomas McCauley as chief scientific officer to lead scientific strategy, pipeline expansion, and execution across its RNA medicines platform.

McCauley most recently served as president and CEO of Neptune Bio.

He previously held chief scientific officer roles at Omega Therapeutics, Macrolide Pharmaceuticals, and Translate Bio.

Stoke’s lead investigational medicine, zorevunersen, remains in development as a potential disease-modifying treatment for Dravet syndrome.